autologous cancer cell vaccine

An autologous cancer cell vaccine is a personalized immunotherapy composed of a patient's own tumor cells that have been harvested and processed in vitro. The vaccine is designed to present the full spectrum of the patient's unique tumor-associated antigens to their immune system. Upon re-administration, typically via intradermal injection, the vaccine aims to stimulate a robust cytotoxic T-lymphocytic response specifically targeted at the tumor cells, potentially leading to tumor regression and improved survival. This approach is particularly explored in patients with advanced solid tumors who have failed standard therapies. A pilot study conducted by UniFontis evaluated this therapy across multiple cancer types, including breast, colorectal, and pancreatic cancers, demonstrating a favorable safety profile and evidence of anti-tumor activity.

Other names

autologous cell vaccine